ALL NEWS

6399 RESULTS

Sort By:

AD Biomarker Labs Can Get Standard Protocol, Quality Control

Did you know that if you had a spinal tap for a cerebrospinal fluid-based Alzheimer's diagnosis in Boston, Stockholm, London, or San Diego, the readout would likely be different in each place? And different again this year and next? That's a pro

Guidelines Bring Needed Change, Though Not Enough for Some

U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.

Task Force Focuses on Tracing Brain Amyloid

Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how a

ALS Ice Bucket Challenge Returns for a Repeat Performance in 2015

Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b

A Contentious Hypothesis About Where and How PD Starts

A contentious hypothesis about where and how Parkinson’s disease starts off is gaining ground as new studies provide clues in its support. Neuroanatomists Heiko Braak and Kelly Del Tredici, both at the University of Ulm in Germany, have described the dist

The Mega-Appeal of Nanomedicine

The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD

Brain Training—Plain Gaming, or a New Vein for Preclinical Research?

If you listen to National Public Radio, watch TV, or surf the Web, chances are you have come across commercials enticing you to “improve your memory” and “unlock your inner genius” with “brain training developed by neuroscientists.”  In search of solid ev

Fallout Continues After Aducanumab Approval

Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime

Learn the Skinny on iPS Cells in Neurodegenerative Disease

Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does

The Alzheimer's Disease Neuroimaging Initiative

The Alzheimer's Disease Neuroimaging Initiative is the most expensive AD study the NIH has ever funded. Expectations are that it will speak with the authoritative voice of a 58-center, three-year observation of 819 research participants above a curre

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE